Acumen research and consulting estimates that the global autoimmune disease therapeutics market is anticipated to reach market size of around US$ 155 Bn by 2027 and is anticipated to grow at a CAGR of around 4% in terms of revenue during the forecast period 2020 – 2027.

An autoimmune disease causes the own body tissue to be damaged. There are more than 80 different types of autoimmune disorder; however, the most common form of autoimmune disorder is lupus, multiple sclerosis, IBS, diabetes type 1, rheumatoid arthritis, psoriasis, and others. Approved for autoimmune disorders therapies include various types of drugs such as antiinflammatory medicines, NSAIDs, interferons, immune suppressants, corticosteroids etc.

Market Insights

Increasing prevalence of autoimmune disease combined with growing public awareness and increasing automation of laboratories which simultaneously diagnose several diagnostic tests to produce rapid and error-free results are factors that contributes the growth of global autoimmune therapeutic market. Furthermore, the market growth was driven in the near future by technological advances such as the development of new biomarkers, including Enbrel, Humira and mobile diagnostic tools. However, the major restraining factor that may impede the growth of global demand of autoimmune diseases therapeutic market such as insufficient financing of developed countries , high cost of disease diagnosis and limited quality of drugs in development countries and the emergence of new technologies.

The autoimmune disease therapeutics market is classified as type 1 diabetes, rheumatic disease, inflammatory bowel disease, multiple sclerosis, and other indications. pIn 2019, the rheumatoid disease had almost half the market share of autoimmune diseases therapeutics, with strong presence of pipeline products , high prevalance for arthritis , Fibromyalgia, systemic lupus erythematosus, gout, scleroderma, rheumatic polymyalgia and other disorders predicted to stay prevalent throughout the forecast period.

Report coverage

The market research study on “Autoimmune Disease Therapeutics Market (By Drug class: Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons, Others; Bu Indication: Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other Indications; By Sales Channel: Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Store)- Global Industry, Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global autoimmune disease therapeutics market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global autoimmune disease therapeutics market are drug class, type, distribution channel and major geographic regions. The autoimmune disease therapeutics market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.

North America accounts to hold large market share of the global autoimmune disease therapeutics market due to increasing prevalence of different types of autoimmune disorders and presence of government rules and regulations regarding health care such as Affordable Care Act and Patient Protection Act. Also, increasing healthcare spending in the region is also likely to flourish the market growth during forecast period. According to National Institute of Health estimates in the U.S. the annual spending on autoimmune disease therapeutics is projected to be US$ 100 Bn. Europe hold the second largest market share of the global market due to growing prevalence of autoimmune diseases, increasing government focus for improving healthcare infrastructure in the region, and increasing adoption of new technologies such as novel biomarkers and portable diagnostics equipment. The presence of significant untapped opportunities in East Europe will, however, drive market growth in auto-immune diseases therapeutic in future years. Asia-Pacific offers lucrative prospects for development for the major players in the autoimmune diseases therapeutic markets due to its broad customer base, rise in acquisition power, an improvement in the prevalence of autoimmune diseases and growing demand for advanced therapeutic autoimmune diseases. The increase in the number of aging people and the early diagnosis of disease with an increase in health spending is likely to fuel the development of the autoimmune market. The Middle East & Africa holds the lowest market share due to poor medical facilities, and lack of technical knowledge.

Key Players

Major players included in this report are AbbVie Inc., Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb Company, AstraZeneca plc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Johnson & Johnson, UCB S.A., and others.

The global autoimmune disease therapeutics market is segmented as below:

Market Segmentation

Autoimmune Disease Therapeutics Market By Drug Class

• Anti-inflammatory
• Antihyperglycemics
• NSAIDs
• Interferons
• Others

Autoimmune Disease Therapeutics Market By Indication

• Rheumatic Disease
• Type 1 Diabetes
• Multiple Sclerosis
• Inflammatory Bowel Disease
• Other Indications

Autoimmune Disease Therapeutics Market By Sales Channel

• Hospital Pharmacy
• Drug Store & Retail Pharmacy
• Online Store

Autoimmune Disease Therapeutics Market By Geography

North America

• U.S
• Canada

Europe

• UK
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENT